Christina K. Ullrich

Mar 4, 2024 | healio.com | Christina K. Ullrich |Patrick Johnson |Mindy Valcarcel

You've successfully added to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Adoptive cellular therapies such as chimeric antigen receptor T-cell therapy have transformed the landscape of care for patients with relapsed or refractory hematologic malignancies.